-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 6, LEO Pharma, a multinational pharmaceutical company specializing in Dermatology and Thrombosis, announced that it has signed a research cooperation license agreement with drug discovery company X-Chem to jointly develop new skin indications Therapeutic drugs
According to the agreement, X-Chem will use its proprietary DNA Encoded Compound Library (DEL) to screen multiple potential FIC (first-in-class) or BIC (best-in-class) targets for LEO Pharma.
Thorsten Thormann, the head of LEO Pharma's research and development, said that the development of FIC (first-in-class) or BIC (best-in-class) drugs in the field of dermatology and changing the standard of care for patients with skin diseases are the direction of LEO Pharma’s ongoing efforts.